- SID Score
- 7.4/10
- Fair value
- $497.35
- Generated
- Sep 3, 2026
- Model
- claude-haiku-4-5-20251001
UnitedHealth Group (UNH) is trading at $399.66 with a market capitalization of $305 billion, representing a mature healthcare company with a fair value estimate of $497.35, implying 26.6% upside potential. The stock carries a SID Score of 7.4/10 and demonstrates mixed factor performance with strengths in Growth (B) and Dividends (B) but weaknesses in Value (D) and Profitability (C). Current analyst consensus is "Buy" with an average price target of $387.80, suggesting limited near-term upside despite the higher fair value estimate. The company maintains a modest dividend yield of 0.03%, typical for growth-oriented healthcare firms prioritizing reinvestment.
UNH demonstrates strong earnings momentum with recent results consistently beating expectations, including a 31.5% EPS beat in July 2026 (actual $6.38 vs. estimated $4.85) and a 10.2% beat in April 2026 ($7.23 vs. $6.56). The P/E ratio of 17.38 reflects moderate valuation relative to growth prospects, though the "D" grade in Value suggests the stock may not offer compelling pricing for value investors. However, the substantial 26.6% gap between current price and fair value estimate of $497.35 indicates potential undervaluation from a fundamental perspective. The B-grade in Growth and consistent earnings outperformance suggest the company maintains strong operational execution and market position within healthcare services.
The stock is trading below its 50-day moving average of $412.40, indicating recent weakness despite being above the 200-day moving average of $343.42, suggesting an intermediate-term uptrend remains intact. The RSI(14) of 42.9 indicates oversold conditions without extreme weakness, providing potential for mean reversion and recovery toward resistance levels. Price action shows the stock has pulled back from recent highs, creating a potential accumulation opportunity for longer-term investors. The technical setup suggests UNH is positioned in a consolidation phase, with the moving average spread indicating gradual uptrend continuation.
Analyst & Insider Sentiment
Insider activity presents a mixed picture with recent selling pressure from executives Conway Patrick Hugh (sold 31,825 shares in August) and Stankiewicz Dennis Andrew (sold 10,058 shares in August), potentially signaling caution at current levels. Conversely, MCNABB Frederick William III and Gil Kristen executed buy transactions in July, suggesting some insider confidence despite recent selling activity. The "Buy" consensus from analysts with a $387.80 average price target contrasts with the higher $497.35 fair value estimate, indicating analyst targets may be conservative. The neutral news sentiment and lack of significant catalysts suggest the market is processing the company without major near-term drivers.
The "C" grade in Profitability raises concerns about margin sustainability and operational efficiency, which are critical in the competitive healthcare services sector. Recent insider selling by senior executives could indicate concern about valuation or forward-looking business performance, warranting monitoring. The modest dividend yield of 0.03% provides minimal income protection if growth stalls, leaving investors reliant on capital appreciation. Regulatory and reimbursement pressures in healthcare, combined with the gap between analyst targets and fair value estimates, create uncertainty regarding appropriate valuation levels.
UnitedHealth Group presents a moderately attractive opportunity for growth-oriented investors with a 26.6% upside to fair value of $497.35, supported by consistent earnings beats and a B-grade growth profile. The stock's current weakness, with RSI at 42.9 and trading below its 50-day moving average, creates a technically attractive entry point for long-term healthcare sector exposure. While the P/E of 17.38 and Value grade of D suggest the stock is not cheap, the operational momentum and analyst "Buy" consensus support patient accumulation for investors with 12-24 month horizons. Conservative investors should wait for either confirmation of the uptrend through price recovery above $412.40 or additional earnings confirmation before establishing positions.
